FLOWOOD, Miss. , Aug. 18, 2022 /PRNewswire/ -- Zavation Medical Products ("Zavation" or the "Company"), an innovative designer and manufacturer of high-quality spinal implants, instruments, MIS procedural kits, and biologics headquartered in Flowood, MS, announced the FDA 510K Clearance of Varisync™, a cervical intervertebral body fusion device.
Zavation Medical Products, LLC, receives FDA 510K Clearance for Varisync™ Anterior Cervical Plate and Spacer system as an addition to its cervical spine portfolio.
Varisync™, the most recent addition to the Zavation cervical spine portfolio, has been tested and approved for both the independent and synchronized use of its plate and spacer components. This allows Zavation's surgeon partners to use these plate and spacer options together as a system or pair individual components with any of Zavation's existing cervical portfolio options. The Varisync™ plate has been thoughtfully designed and boasts attributes that include visual and tactile confirmation of locks, ideal screw angulation, multiple insertion devices, and optimal spacer placement in the disc space.
Zavation's market share and active surgeon base continues to rapidly grow given the Company's ability to adapt to surgeon/patient needs, consistently upgrade its instruments, and engineer devices with incomparable simplicity and precision. Zavation's sustained investment in research and development will further enhance its technologies and accelerate market share and active surgeon base gains.
"Our product development team's dedication to creatively blending simplicity and precision in a robust product design has produced a product that we believe is the new gold standard in facilitating patient fusion in a seamless and simplified procedure," said Jeffrey Johnson, Chief Executive Officer "With the extensive interbody offerings that Zavation boasts, it only makes sense that we develop a device, that allows surgeons to easily integrate and place a plate and spacer combination of their choice." This product is an example of Zavation's commitment to offering innovative and differentiated products in conjunction with market leading customer service to best serve our surgeons and distributor network."
The VariSync™ Plate is intended for anterior screw fixation to the cervical spine (C2-C7) for the following indications: degenerative disc disease (as defined by neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), trauma (including fractures), tumors, deformity (defined as kyphosis, lordosis, or scoliosis), pseudarthrosis, failed previous fusion, spondylolisthesis, and spinal stenosis.
The VariSync™ Spacer is an interbody fusion device intended for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine (C2-T1) at one level. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) weeks of non-operative treatment. The VariSync™ Spacer is to be filled with autograft or allogenic bone graft comprised of cancellous and/or corticancellous bone graft in skeletally mature patients. These devices are intended to be used with supplemental fixation such as the Zavation VariSync™ Plate, Zavation Midline Plate, Zavation EZ Plate, or Zavation Cervical Plate Systems. When used with the VariSync™ Plate, the assembly takes on the indications of the VariSync™ Spacer, with the VariSync™ Plate acting as the supplemental fixation.
ABOUT ZAVATION MEDICAL PRODUCTS, LLC.
Based in Flowood, MS, Zavation designs, engineers, and manufactures a portfolio of spinal hardware and biologics covering key areas including cervical, thoracolumbar, interbody fusion, interventional spine, and minimally invasive surgery. Founded in 2012, Zavation has experienced exceptional growth and created a national network of numerous distributors across the United States. The Company has commercialized over 25 product families since inception. Zavation operates a newly constructed 75,000 square foot vertically integrated facility in Flowood, MS. To learn more information about Zavation and the Company's suite of products, visit www.zavation.com.
Related Links www.zavation.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zavation-medical-products-llc-receives-fda-510k-clearance-for-varisync-anterior-cervical-plate-and-spacer-system-as-an-addition-to-its-cervical-spine-portfolio-301608024.html
SOURCE Zavation Medical Products, LLC.
The Food and Drug Administration authorized Novavax Inc.'s COVID-19 vaccine for use in U.S. teenagers on Friday. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. and BioNTech SE , and received an emergency-use authorization by the FDA for adults in July. The vaccine still requires a policy recommendation for use by the Centers for Disease Control, which followed the FDA by about a week when authorizing the Novavax shot for adults
The Food and Drug Administration approved a new depression pill from Axsome Therapeutics on Friday, and AXSM stock catapulted higher.
President Joe Biden signed the wide-ranging Inflation Reduction Act (IRA) into law on Tuesday afternoon, bringing welcome news for many retirees.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received expanded emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus
U.S. based monkeypox vaccine manufacturer targets December for first batch of doses for delivery.
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Yahoo Finance's Brian Cheung discusses reports that a depression drug from Axsome Therapeutics has gotten FDA clearance.
Medicare beneficiaries are in for some big savings under the Inflation Reduction Act, which is ushering in a new era of negotiating drug prices and capping out-of-pocket expenses. The Inflation Reduction Act has a few key components that specifically target the needs of the older Americans Medicare covers — three will be effective at the beginning of 2023, and the rest in a few years. Biden signed the Inflation Reduction Act earlier this week–it is considered a major win for Democrats with its focus on healthcare spending, climate change and corporate taxation.
Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.
A study published this week in the Lancet Psychiatry showed increased risks of some brain disorders two years after infection with the coronavirus, shedding new light on the long-term neurological and psychiatric aspects of the virus. The analysis, conducted by researchers at the University of Oxford and drawing on health records data from more than 1 million people around the world, found that while the risks of many common psychiatric disorders returned to normal within a couple of months, peo
(Reuters) -Axsome Therapeutics Inc on Friday gained U.S. approval for its treatment for depression, giving more than 20 million Americans affected by the disorder a new option in a market crowded by older drugs. The drug, Auvelity, is a new class of treatment that reduces the symptoms of depression as early as one week, giving it a potential edge over older antidepressants, which can take up to six weeks to show effect. The treatment has "blockbuster" potential, but the company will have to make significant investment to build the market for a new branded therapy in a field full of generic therapies, Guggenheim analyst Yatin Suneja wrote in a client note.
The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new recommendations for using two monoclonal antibodies. Following a systematic review and meta-analysis, WHO recommended two monoclonal antibody treatments, Ebanga (Ansuvimab, mAb114) and Inmazeb (REGN-EB3). Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Inmazeb became the first treatment for the ebola virus when it received FDA approval in October 2020. Merck & Co Inc's (NYSE: MRK)
The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.
The U.S. Food and Drug Administration issued a rule Tuesday to allow certain types of hearing aids to be made available over-the-counter without the need for a prescription or medical examination. Dr. Amit Gosalia talked about how to know if the hearing aids are right for you.
People with compromised immune systems should avoid raw seafood, the CDC says.
Nearly 1 in 3 Americans haven’t been to the dentist since before the COVID-19 pandemic began. Why?
An Arizona attorney on Friday urged a judge to allow the state to enforce a near-total ban on abortions under a law that has been blocked for nearly 50 years through a now-overruled U.S. Supreme Court decision. Assistant Attorney General Beau Roysden said the judge's role is simple: now that the high court has overturned Roe v. Wade, the 1973 ruling that legalized abortion, Pima County Superior Court Judge Kellie Johnson should lift an injunction preventing enforcement of that law. Planned Parenthood and its Arizona affiliate argued that the judge should only allow the law to be enforced against people who are not doctors so that other abortion restrictions that the Legislature has enacted since Roe remain relevant.
Story at a glance As of 2017, approximately 5.4 million U.S. adults have autism spectrum disorder. Results of the large study may help drive future treatments for the condition. Researchers also hope findings will spur genetic testing to identify those at risk. An analysis of over 150,000 people, 20,000 of whom have autism, revealed over…
The sector had tumbled in the market selloff, but it is getting a boost from big investors and big pharmaceutical companies.
A Texas woman had quite a scare on Tuesday after she was rushed to the emergency room for acute poisoning, The Shade Room reports.